TrialNet: Diabetes Type 1 Prevention

TrialNet：1 型糖尿病预防

• 批准号: 9268733
• 负责人: PETER A GOTTLIEB
• 金额: $ 58.72万
• 依托单位: UNIVERSITY OF COLORADO DENVER
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-09-30 至 2019-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9268733
• 关键词: Ancillary Study; Autoimmune Diseases; Autoimmune Process; B-Lymphocytes; Blood Glucose; C-Peptide; Cell Compartmentation; Clinical; Clinical Research; Conduct Clinical Trials; Development; Diabetes Mellitus; Dietary Intervention; Disease; Disease Progression; Enrollment; Functional disorder; Future; Goals; Healthcare Systems; Human; Immune; Immune Tolerance; Immunologic Markers; Immunologics; Immunotherapy; Insulin-Dependent Diabetes Mellitus; Intervention; Knowledge; Metabolic; Participant; Pathogenesis; Physicians; Populations at Risk; Prevention; Productivity; Protocols documentation; Recruitment Activity; Scientist; Study Subject; T-Lymphocyte; United States; Work; cost; human subject; impaired glucose tolerance; improved; monocyte; next generation; polypeptide C; prevent; public health relevance

DESCRIPTION (provided by applicant): Multiple treatments that can change the course of type 1 diabetes have been identified over the last several years through the efforts of TrialNet, the Immune Tolerance Network and others. Although these immune therapies can stop disease progression in those with elevated blood sugars, the effect has proven to be transient in most study subjects. The ongoing effort of Type 1 Diabetes TrialNet, its Clinical Centers and affiliates is to continue to develop better therapies to prevent and reverse type 1 diabetes in human subjects. The Barbara Davis Center and its affiliate network has been a central contributor to these efforts from the beginning of DPT-1 through TrialNet and we hope with renewal of our Clinical Center to be able to continue to push towards these aims as well as develop the next generation of physician-scientists who can build on the work accomplished so far. Our aim is not only to conduct excellent clinical research which can answer the main study questions being examined: most often metabolic - development of impaired glucose tolerance, overt diabetes or reduced C-peptide, but also to develop immune biomarkers which can help us better understand the pathogenesis of disease progression and identify secondary markers of responder groups that allow us to better tailor our therapies to achieve successful prevention of T1D.

描述（申请人提供）：通过试验网，免疫耐受性网络等，在过去几年中，已经确定了可以改变1型糖尿病进程的多种治疗方法。尽管这些免疫疗法可以阻止血糖升高患者的疾病进展，但事实证明，在大多数研究对象中，这种作用已是短暂的。 1型糖尿病试验网，其临床中心和分支机构的持续努力 是继续开发更好的疗法，以预防和反向人类受试者中的1型糖尿病。芭芭拉·戴维斯中心（Barbara Davis Center）及其会员网络一直是从DPT-1开始到试验网络的核心贡献者，我们希望能够续签我们的临床中心，能够继续朝着这些目标迈进，并发展下一代的医生科学家，他们能够在迄今为止的工作中建立工作。我们的目标不仅是进行出色的临床研究，可以回答正在研究的主要研究问题：最常见的代谢 - 发展受损的葡萄糖耐受力，明显的糖尿病或C肽降低，而且还可以发展免疫生物标志物，这可以帮助我们更好地了解疾病的病原体的病原体，并能够更好地了解我们的次数级别，从而使我们的次数能够更加成功地培养。